- AU$92.14m
- AU$90.96m
- AU$117.34m
- 62
- 89
- 37
- 66
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 4.59 | ||
PEG Ratio (f) | 0.27 | ||
EPS Growth (f) | 20.68% | ||
Dividend Yield (f) | 6.25% |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 2.35 | ||
Price to Tang. Book | 11.14 | ||
Price to Free Cashflow | 8.56 | ||
Price to Sales | 0.77 | ||
EV to EBITDA | 6.41 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 27.22% | ||
Return on Equity | 27.73% | ||
Operating Margin | 11.27% |
Financial Summary
Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | AU$m | n/a | 0.12 | 21.71 | 66.99 | 117.34 | 156.8 | 188.2 | n/a |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | +251.84 | +94.44 | +24.22 | +20 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Vitura Health Limited is a diversified digital health company that operates various businesses via its subsidiaries CanView, Doctors on Demand, Cortexa, CDA Clinics, Cannadoc, BHC and Adaya. It consists of Medical segment involving the sale and distribution of medicinal cannabis products; Clinics segment involving the operation of medicinal cannabis clinics, and Consumer segment involving the sale of consumer (non-medical) products in both Australia and Asia. Burleigh Heads Cannabis operates the prescriber, patient, pharmacy and supplier online platform, CanView, which sells and distributes 350+ therapeutic products and device stock-keeping units (SKUs) within Australia from medicinal cannabis producers. It also owns Doctors on Demand Pty Ltd, a telehealth platform business that provides primary health solutions. It owns 75.5% Cannadoc Health Pty Ltd, a medicinal cannabis clinic business that undertakes telehealth consultations with patients seeking access to medicinal cannabis.
Directors
- Shane Tanner NEC
- Rodney Cocks CEO
- Thomas Howitt CFO
- Guy Headley DRC
- Benjamin Jansen DRC
- Kurt Schmidt DRC (64)
- Marcia Walker DRC
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- September 27th, 2018
- Public Since
- November 7th, 2019
- No. of Employees
- 121
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 575,873,788
- Address
- Suite 8, Melbourne, 3141
- Web
- https://www.vitura.com.au/
- Phone
- +61 300799491
- Auditors
- Pilot Partners
Upcoming Events for VIT
Similar to VIT
Acrux
Australian Stock Exchange - SEATS
AFT Pharmaceuticals
Australian Stock Exchange - SEATS
Althea group
Australian Stock Exchange - SEATS
Argent BioPharma
Australian Stock Exchange - SEATS
Auscann group
Australian Stock Exchange - SEATS
FAQ
As of Today at 19:24 UTC, shares in Vitura Health are trading at AU$0.16. This share price information is delayed by 15 minutes.
Shares in Vitura Health last closed at AU$0.16 and the price had moved by -48.39% over the past 365 days. In terms of relative price strength the Vitura Health share price has underperformed the ASX All Ordinaries Index by -50.63% over the past year.
The overall consensus recommendation for Vitura Health is Buy. You can view the full broker recommendation list by unlocking its StockReport.
The Vitura Health dividend yield is 6.25% based on the trailing twelve month period.
Last year, Vitura Health paid a total dividend of AU$0.01, and it currently has a trailing dividend yield of 6.25%. We do not have any data on when Vitura Health is to next pay dividends.
We do not have data on when Vitura Health is to next pay dividends. The historic dividend yield on Vitura Health shares is currently 6.25%.
To buy shares in Vitura Health you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$0.16, shares in Vitura Health had a market capitalisation of AU$92.14m.
Here are the trading details for Vitura Health:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: VIT
Based on an overall assessment of its quality, value and momentum Vitura Health is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Vitura Health is AU$0.70. That is 337.5% above the last closing price of AU$0.16.
Analysts covering Vitura Health currently have a consensus Earnings Per Share (EPS) forecast of AU$0.03 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vitura Health. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -62.53%.
As of the last closing price of AU$0.16, shares in Vitura Health were trading -47.75% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Vitura Health PE ratio based on its reported earnings over the past 12 months is 4.59. The shares last closed at AU$0.16.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Vitura Health's management team is headed by:
- Shane Tanner - NEC
- Rodney Cocks - CEO
- Thomas Howitt - CFO
- Guy Headley - DRC
- Benjamin Jansen - DRC
- Kurt Schmidt - DRC
- Marcia Walker - DRC